Analysis Identifies Factors Prognostic of Ruxolitinib Failure in Chronic GVHD

Updated results from a real-world analysis confirm that ruxolitinib is an effective treatment option for patients with chronic graft-versus-host disease (GVHD), according to a poster presented at the 2021 ASH Annual Meeting by Jennifer White, MD, MSc, FRCPC, from the British Columbia Cancer Agency and Vancouver General Hospital in Canada. The researchers also identified factors … Continue reading Analysis Identifies Factors Prognostic of Ruxolitinib Failure in Chronic GVHD